The short answer
TRIUMPH-5 (NCT06662383) is a Phase 3 trial comparing retatrutide directly against tirzepatide in 800 adults with obesity. It began in November 2024, and its primary completion was scheduled for November 2026. It will be the first head-to-head test of a triple agonist against a dual agonist.
Key facts
- Registration
- NCT06662383
- Acronym
- TRIUMPH-5
- Comparison
- Retatrutide vs tirzepatide (LY3298176)
- Phase
- 3
- Enrolment
- 800 participants
- Started
- 1 November 2024
- Primary completion
- Scheduled for November 2026
- Status
- Active, not recruiting
Why a head-to-head matters more than another placebo trial
Every comparison currently made between retatrutide and tirzepatide is indirect: TRIUMPH-1's 28.3% against SURMOUNT-1's 20.9%, from separate trials with different populations, durations and estimands. Indirect comparison is the weakest form of evidence for this question. TRIUMPH-5 randomises the same population to both drugs at the same time for the same duration, which removes nearly every confound at once.
What is being tested
Retatrutide is a triple agonist engaging GIP, GLP-1 and glucagon receptors. Tirzepatide is a dual agonist engaging GIP and GLP-1. Both are Eli Lilly compounds built on modified GIP scaffolds, so the trial isolates one variable fairly cleanly: what the glucagon-receptor arm adds. That is an interesting scientific question as well as a commercial one.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Scale and timing
The trial enrolled 800 participants, began on 1 November 2024, and its primary completion was scheduled for November 2026. It is listed as active but no longer recruiting. Primary completion is when the last participant completes the primary outcome measurement. It is not the date results are published, and topline release typically follows some months later.
What it will and will not settle
It should settle whether a triple agonist outperforms the best available dual agonist on weight reduction, and how the two compare on tolerability at maximum tolerated doses. It will not address durability after cessation, which is a separate question handled by TRIUMPH-6, and it will not produce cardiovascular outcome data, which requires a different trial design entirely.
The regulatory position is unchanged
Tirzepatide holds marketing authorisations. Retatrutide holds none anywhere, and a head-to-head trial does not alter that. Lilly has signalled an FDA filing in the first quarter of 2027. Nothing in this trial makes retatrutide available outside a registered study, and material supplied for laboratory research is not related to either product.
Frequently asked questions
When will TRIUMPH-5 results be available?
Primary completion was scheduled for November 2026. That is when the last participant completes the primary measurement; topline results typically follow some months later.
Why compare two drugs from the same company?
Because it isolates the scientific question. Both are built on modified GIP scaffolds, so the main difference is retatrutide's glucagon-receptor activity.
Does this mean retatrutide is close to approval?
No. It remains investigational everywhere. Lilly has signalled an FDA filing in Q1 2027, and filing begins a review rather than ending one.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- TRIUMPH-6: Maintenance of Weight ReductionTRIUMPH-6 tests whether reduction is sustained on maintenance dosing. 643 participants, primary completion April 2028 - the field's key question is years away.
- Retatrutide Expanded Access: What It Actually IsA pre-approval expanded access record for retatrutide is listed as available. What expanded access means, who it is for, and what it is emphatically not.
- The Compounded GLP-1 CrackdownThe FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B Bulks List in April 2026, closing the last legal route for mass compounding.
- MHRA Drug Safety Update: Semaglutide and NAIONOn 5 February 2026 the MHRA warned of a likely association between semaglutide and NAION, a rare optic neuropathy, estimated at up to 1 in 10,000 users.
- Target Trial Emulation: Making Observational Data BehaveA method for analysing routine health records as though a trial had been designed. Why it exists, what it fixes, and what it cannot fix.